The role of long non-coding RNAs in BCR-mediated CLL activation.

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14740%2F23%3A00132967" target="_blank" >RIV/00216224:14740/23:00132967 - isvavai.cz</a>

Výsledek na webu

<a href="https://www.ceitec.eu/ceitec-phd-conference-2023/a4489" target="_blank" >https://www.ceitec.eu/ceitec-phd-conference-2023/a4489</a>

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

The role of long non-coding RNAs in BCR-mediated CLL activation.

Popis výsledku v původním jazyce

B cell Receptor (BCR) plays a pivotal role in providing maturation and survival signals for B cells. However, dysregulation of the BCR pathway is a fundamental characteristic observed in numerous B cell malignancies, including chronic lymphocytic leukemia (CLL), revealing its importance in disease progression. Despite the absence of recurrent mutations found in the BCR-related genes of untreated cases, BCR inhibitors have shown a universal clinical response in CLL patients. We and others have shown that short non-coding RNAs, namely microRNAs, can (dys)regulate the BCR signaling propensity, but it is still unclear if long non-coding RNAs (lncRNAs) play a role in BCRactivation. Hence, we hypothesized that lncRNAs could be involved in BCR-mediated CLL activation. To address our hypothesis, we performed differential lncRNA expression analysis in CLL cells from patients treated with BCR inhibitors and cross-validated in CLL intraclonal subpopulations with high BCR activity (CXCR4dim CD5bright) vs. low BCR activity (CXCR4bright CD5dim). We found 12 lncRNAs related to the BCR pathway inhibition/activity. Out of these lncRNAs, we selected a lncRNA that belongs to a class of lncRNA called long intergenic non-coding RNA (lincRNAs) which often play a role in trans-activating signaling pathways.

Název v anglickém jazyce

The role of long non-coding RNAs in BCR-mediated CLL activation.

Popis výsledku anglicky

B cell Receptor (BCR) plays a pivotal role in providing maturation and survival signals for B cells. However, dysregulation of the BCR pathway is a fundamental characteristic observed in numerous B cell malignancies, including chronic lymphocytic leukemia (CLL), revealing its importance in disease progression. Despite the absence of recurrent mutations found in the BCR-related genes of untreated cases, BCR inhibitors have shown a universal clinical response in CLL patients. We and others have shown that short non-coding RNAs, namely microRNAs, can (dys)regulate the BCR signaling propensity, but it is still unclear if long non-coding RNAs (lncRNAs) play a role in BCRactivation. Hence, we hypothesized that lncRNAs could be involved in BCR-mediated CLL activation. To address our hypothesis, we performed differential lncRNA expression analysis in CLL cells from patients treated with BCR inhibitors and cross-validated in CLL intraclonal subpopulations with high BCR activity (CXCR4dim CD5bright) vs. low BCR activity (CXCR4bright CD5dim). We found 12 lncRNAs related to the BCR pathway inhibition/activity. Out of these lncRNAs, we selected a lncRNA that belongs to a class of lncRNA called long intergenic non-coding RNA (lincRNAs) which often play a role in trans-activating signaling pathways.

Druh

O - Ostatní výsledky

CEP obor

—

OECD FORD obor

30204 - Oncology

Projekt

Výsledek vznikl pri realizaci vícero projektů. Více informací v záložce Projekty.

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2023

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů